Clinical Research Directory

Inclusion Criteria: * Adults (male or female) between ages of 30 - 75 years * Should have Type 2 diabetes mellitus * With Insulin requirement of 0.7 IU/kg/d or 50 IU/d, whichever is lesser * Glutamic acid decarboxylase (GAD) antibody status should be negative * Body Mass Index (BMI) 19 - 30 kg/m2 * Fasting blood glucose (FBG) should be ≥ 7.0 mmol/L, and HbAc1 ≥ 7% * Intravenous insulin tolerance tests (ITT) indicate a patient's insulin resistance * Should be ambulatory and in good general health * Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions * Willing to abstain from the use of protocol-restricted treatments from Screening through the End-of-Treatment * No clinically significant abnormalities observed in medical history, physical exam vital signs, and laboratory assessments * For females with reproductive potential: Should agree to use effective contraception for at least 1 month prior to screening and should agree to use such a method till end of the study period and negative pregnancy test * For males with reproductive potential: should use condoms and other methods to ensure effective contraception with a partner Exclusion Criteria: * Subjects with Type 1 Diabetes Mellitus (T1DM) or secondary diabetes * Subjects with serum creatinine 1.5 mg/dl or higher * Abnormal liver function test (defined as value of transaminases \> 3 times the upper limit of normal or serum bilirubin higher than normal for the reference value for the laboratory) * History of myocardial infarction or unstable angina in previous 3 months * History of malignancy or current malignancy other than non-melanomatous skin cancer * Subjects with active infections * Subject with serious medical conditions other than cardiovascular disease * Subject with, or with a medical history of auto-immune diseases * Subject with a medical history of mental disorder or epilepsy * Subject abuse alcohol 10 times a week or smoke 25 cigarettes a day * Subject who was diagnosed with cancer within 5 years before screening * Subject who participated in another clinical trial within 6 months prior to the screening of this clinical trial * Subject who was administered with immunosuppressants such as cyclosporin A or azathioprine within 6 weeks prior to the screening * Serious life-threatening conditions * Allergies to anesthesia * Subject who is pregnant or nursing * Subject is on chronic immunosuppressive transplant therapy * Subjects who tested positive for HIV 1/2, HBV, HCV, HTLV I/II, WNV, and syphilis * Flu symptoms * Any past history of lipid disorders: lipedema, lipomatosis, or lipodystrophies * Active cancer, chemotherapy, or other malignancies in the last 6 months prior to the screening * Any past history of DVT or pulmonary embolism requiring anticoagulants or other medicines * Requiring supplemental oxygen * Major surgeries within 6 months prior to the screening * Wounds/sepsis ongoing or within 3 months prior to the screening * Any illness which in the Investigator's judgment, may interfere with the subject's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results